Nabriva Therapeutics: Presented data on lead pleuromutilin antibiotic lefamulin (BC-3781) at the 54th Interscience conference on antimicrobial agents and chemotherapy in Washington DC

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for treatment of serious infections caused by resistant pathogens, today announced the presentation of a poster on BC‑3781, a novel pleuromutilin antibiotic which is being developed for oral and intravenous administration for the treatment of severe infections, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington DC on Sunday 7th September, from 11am to 1pm EDT.

Dr Colin Broom, Chief Executive Officer of Nabriva, commented: “These data are highly encouraging for BC-3781 and provide strong support for our late stage development plans for community acquired bacterial pneumonia and other respiratory infections. We are delighted that the organizers accepted these data for presentation at such a prestigious conference.”

The following poster was presented in the Clinical Pharmacology of Anti-Infective Agents in Clinical Development session:

Pharmacokinetics of BC-3781 in the Pulmonary Epithelial Lining Fluid of Healthy Subjects
M. Zeitlinger, D. B. Strickmann, W. W. Wicha, R. Schwameis, B. Burian, M. Müller, W. T. Prince;
1Med. Univ. of Vienna, Vienna, Austria, 2Nabriva Therapeutics AG, Vienna, Austria

The study examines the pharmacokinetics (PK) of BC-3781 in the epithelial lining fluid in comparison to the plasma. Since knowledge of the PK at the site of infection is crucial in the development of antibiotics, for the treatment of respiratory tract infections such as community- and hospital-acquired bacterial pneumonia (CABP & HABP) drug penetration in to the pulmonary epithelial lining fluid (ELF) is a pre-requisite. The study, whereby BC-3781 was administered to 12 healthy male subjects, was safe and well tolerated and there were no clinically relevant changes in laboratory values. Main conclusions found were that after a single intravenous dose of BC-3781, exposure levels in ELF were comparable to total plasma levels and considerably exceeded free plasma levels. The individual BC-3781 concentration levels in ELF equilibrated with the plasma rapidly after the end of infusion.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)